Craig-Hallum analyst Albert Lowe downgraded Rezolute (RZLT) to Hold from Buy with a $2 price target after the Phase 3 study of ersodetug in congenital hyperinsulinism missed its endpoint.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute price target lowered to $5 from $17 at BTIG
- Rezolute downgraded to Market Perform from Outperform at Citizens
- Rezolute downgraded to Neutral from Overweight at Cantor Fitzgerald
- Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss
- Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug